SCI Abstract

search
A review of international initiatives on pharmaceutical regulatory reliance and recognition
Abstract: In light of recent global health challenges, the need for regulatory reliance – where one regulatory authority a...
Comment on the article by Reilly MS and McKibbin RD
Abstract: Reilly and McKibbin oppose the update of FDA interchangeability guidance that does not require clinical switch s...
Comment on ‘Misinformation about interchangeable biosimilars’
Author byline as per print journal: Hillel P Cohen, PhD; Caridad Pontes, MD, PhD; Fernando de Mora, MBA, PhD Abstract: The...
Third and final issue of GaBI Journal’s 13th volume
This third issue of GaBI Journal is the last of the volume for this year and marks the end of the first year of me taking ...
Trends in Saudi FDA drug approvals and GMP inspections: an observational study
Author byline as per print journal: Dr Ali M Alhomaidan; Mohammed Abdulaziz Alageel; Turki Abdulaziz Alrafie; Hassan Moham...
The incorporation of the Halal Management System (HMS) by the pharmaceutical industry
Author byline as per print journal: Ka-Liong Tan1, DPhil; Ainoon Othman1; Irwan Mohd Subri3; Noor Fadzilah Zulkifli1; Mohd...
Biosimilar antibody drug conjugates: considerations of higher order structure and aggregation
Abstract: Undoubtedly the complexity of Antibody Drug Conjugate (ADC) molecules where three components (monoclonal antibod...
Medicare drug price negotiations: impact on healthcare development and patient access to medicines
Author byline as per print journal: Michael S Reilly, Esq; Thomas R Barker, Esq, JD; Charles M Clapton, Steven J Potts, Ph...
Extrapolation requires reading between the lines
The articles in this second issue of 2023 include an Original Research study (Internet questionnaire) of the ‘opinions’ of...
Follow-on biologicals/biosimilars approved in Brazil: May 2023 update
Abstract: Brazilian requirements for approval of biosimilars are aligned with a strict regulatory process and ensure the s...
Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars
Author byline as per print journal: Michael S Reilly, Esq; Jane Barratt, PhD Introduction: The first biosimilar entered th...
Statistical tests for detecting reference product change in biosimilar studies
Author byline as per print journal: Jiayin Zheng1, PhD; Peijin Wang2, MS; Yixin Wang3, PhD; Shein-Chung Chow2, PhD Abstrac...
Lagging acceptance of generic and biosimilar drug products; the rest of the story
The articles in this issue of the GaBI Journal reminded me of The Rest of the Story radio programme originally hosted by M...
Non-medical switching of biologicals/biosimilars Canada, Europe and the US: a webinar report
Author byline as per print journal: Michael S Reilly, Esq; Gail Attara; Ralph D McKibbin, MD, FACP, FACG, AGAF; Professor ...
Biosimilars approved in Brazil 2022
Author byline as per print journal: Sílvia Helena Cestari de Oliveira, MSc Abstract: In Brazil, a legal framework for appr...
Biosimilars drug development: time for a paradigm shift?
Author byline as per print journal: Sandeep N Athalye, MS; Shivani Mittra, MPharm, PhD; Ankitkumar M Ranpura, MD Abstract:...
Response to the Opinion entitled ‘Biosimilars drug development: time for a paradigm shift?’
Abstract: The Opinion published in this issue of GaBI Journal titled 'Biosimilars drug development: time for a paradi...